"A recent review of GLP-1 drugs showed that, compared with the injectable form, oral semaglutide is associated with lower rates of side-effect reporting but higher discontinuation rates, potentially reflecting its bothersome dosage requirements.Despite these hurdles, it seems inevitable that obesity-drug pills will eventually become available."
Read this story from "The Atlantic" for free without being tracked.
#theatlantic #health #Ozempic #Zepbound #Wegovy #Pfizer #Rybelsus